New Ideas.
Better Results.

Blue Matter is a consulting firm serving the life sciences industry. We strive to bring a new approach to consulting with original ideas that deliver a meaningful impact.

Contact Us

Our Purpose

We are proud to be part of an industry that is pushing the boundaries of science and technology to improve people’s lives. Our role is to help our clients identify unique insights, generate new ideas and drive meaningful results to get the most out of their products, portfolios and teams.

We began our careers in established consulting firms where we developed valuable experience and industry knowledge. During this time, we came to see that rigid processes often interfered with original thinking and led to bloated deliverables packed with mediocre answers.

A group of us like-minded, passionate consultants believed there was a better approach and founded Blue Matter to provide a platform to foster innovation and creativity in consulting.

Our Difference

Industry and scientific knowledge, analysis and insights. Left brain thinking. This is the foundation of our discipline. Creativity and imagination. Constantly challenging conventional thinking and seeking fresh ideas. Right brain thinking. We’re passionate about this; it’s the reason our clients come back.

The key to winning is effective differentiation. And effective differentiation comes from originality–thinking that is grounded in reason and infused with imagination.

"The terrific work you did resulted in a substantial change to our commercial strategy."

- Chairman of the Board, Small Biotech

"Thank you very much for the great work and partnership. You are one of the rare breed of consultants whom I trust. You will always be on my speed dial if we need help with anything."

- Chief Commercial Officer, Small Biotech

"I appreciate all of the great work you have done for our team this past year and look forward to continued partnership in the New Year."

- Chief Commercial Officer, Mid-sized Diagnostic Company

"Your preparation and support has been instrumental in achieving our desired outcome."

- Franchise Commercial Lead, Global Biotech

"Thank you all so much for the extremely successful project...I couldn't be happier with the way that it went."

- Sr. Product Manager, Diagnostic Company

"This project was excellent, from the content development to facilitation. Many, many thanks for the great work!"

- Director of Marketing, Diagnostic Company

"The process was great, I loved that I didn't have to manage you that much. Everything was highly organized and done on time. Quality and originality of thinking was also good."

- Global Commercial Lead, Large Biotech

"Great project. I was learning as we went along; good expertise — brought in examples from other projects."

- Global Commercial Lead, Large Biotech

Our Clients

Our clients include: top global bio-pharmaceutical companies with large, diverse product portfolios to small emerging players with one asset in development, leading diagnostic companies, and investment houses. We work with CEOs, Chief Commercial Officers, Franchise Heads, Product Directors, Functional Area Leaders. 90%+ of our business is from repeat, satisfied customers.

Our Services

Shape Innovative Products

Drive Successful Launches

Build Great Portfolios and Companies

Pathfinder Capabilities

Blue Matter offers in-depth market expertise across North American and European markets.

Our Pathfinder offerings are specifically designed to help growing biopharma companies succeed in European markets.

Learn more: 7 Keys to Success in Europe

Want to Join Our Team?

Blue Matter offers enriching project experiences with a diverse range of strategic, client-facing projects in the exciting and innovative life sciences industry.

Join Our Team


Join our team! We're recruiting for 3 #consulting positions, a Learning Specialist, & a Marketing Specialist. Learn…

Join our team! We're seeking a Learning Specialist to join Blue Matter Academy, our in-house…

Key Themes from the 2021 Virtual World Orphan Drug Congress

Some of our Rare Disease team spent a day last week listening to patient experts and industry specialists in a series of virtual panels and fireside chats organized by the World Orphan Drug Congress. Amongst a wealth of interesting topics and a consistent focus on accelerating the delivery of rare disease (RD) therapies, a few … Read More

Introducing our New Presentation Series on Access Evidence Generation

Generating Evidence to Support Market Access Great evidence planning is the foundation to successful market access. While good pricing and negotiation strategies at launch are essential, pharmaceutical companies can dramatically reduce the effort and risk required by having the “right” data that payers are seeking. In this case, “an ounce of prevention is really worth … Read More

Five Trends to Watch in the European Market Access Environment

Every day, the sun rises and the sun sets. Here’s another thing that’s almost as dependable: national payers in Europe are facing increased pressures on their healthcare budgets. Payers want to provide access and fund innovative treatments to improve patient care, but they need to do so in the context of constrained budgets. However, the … Read More

“Taboo” Substances Are Getting Another Look in CNS

Psychedelics and other traditionally taboo substances appear to be undergoing a bit of a “renaissance” in central nervous system (CNS) therapeutics these days.  These types of substances have a long and storied history all around the world.  Now, science is getting serious about exploring ways to use them to treat a range of diseases and … Read More

Blue Matter Statement on Racial Equality and the Tragic Events This Week

At Blue Matter, we stand with the Asian American and Pacific Islander community and condemn all forms of hate, racial discrimination and violence.  We are deeply saddened by the horrific events that took place on Tuesday night near Atlanta, where the majority of those killed were Asian women.  The recent rise in racially motivated violence … Read More

Novel Therapeutics in Oncology: What’s on the horizon, and what’s already here

2021 will be a big year for emerging oncology therapeutics, as we anticipate major late-stage clinical advancements for several new modalities either reaching their first regulatory decision (e.g., TILs, TCR-T, first solid tumor bispecific antibody) or making the leap from newly emerging into more established with new targets or indications beyond their initial approvals (e.g., … Read More

Happy Women’s History Month!

Blue Matter wishes everyone a very happy Women’s History Month – this is an opportunity to discover, document, celebrate and respect women’s lives and achievements. At Blue Matter, we support an inclusive and intersectional feminist work environment where women have the freedom, recognition, and right to be their own powerful selves. We are observing Women’s … Read More